Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
T he long-standing controversy over the validity of the lipid hypothesis of atherosclerosis has been settled.[1][2][3] In several large-scale, 5-year trials, statins have reduced coronary heart disease (CHD) morbidity and mortality by Ϸ30%, and the magnitude of the protective effect mirrored the magnitude of the low-density lipoprotein (LDL) lowering.4 However, as has been quite correctly pointed out, 5,6 some 70% of those expected to have an event (based on the number of events in the control group) went on to have one during the 5 years of the trial despite statin therapy.For example, in the Scandinavian Simvastatin Survival Study, 502 events occurred in the untreated group and 353 in the statin-treated group.The number of events prevented (nϭ149), as a percentage of the number expected, was 29.7% (149/ 502ϫ100); the number of events in the statin group that were not prevented (353) amounts to 70.3% (353/502ϫ100).Looked at this way, the results are admittedly not quite so impressive.In fact, some investigators are now taking the position that we can expect to achieve higher salvage rates only if we supplement LDL-lowering therapies with alternative interventions such as the use of antiinflammatory agents or immunotherapy.This may turn out to be true.However, it is much too early to reach that conclusion for reasons we discuss here.The search for alternative or supplementary therapies is already in full swing and should continue.6 -8 We are confident that one day these additional therapies will take their place alongside cholesterol-lowering agents in our armamentarium.However, we believe that the results of the statin trials to date considerably underestimate the full potential of cholesterol-lowering strategies.It would be unfortunate if efforts to fully exploit that potential faltered because of a misplaced pessimism based on the statin results to date.Our current approaches may be a case of "too little, too late."5,9 -14 How much further can we expect to decrease risk by treating dyslipidemia (ie, lowering LDL levels and/or raising highdensity lipoprotein levels)?Why Do We Think We Can Do Better?One important line of evidence comes from a consideration of the Japanese experience.In 1952, mortality from CHD among Japanese men 55 to 64 years of age was Ͻ10% of what it was in the United States.15,16 Their total cholesterol levels at the time averaged Ϸ160 mg/dL (estimated LDL, Ϸ80 mg/dL).It is noteworthy that the Japanese enjoyed this relative immunity to CHD despite the fact that the prevalence of one of the major risk factors-cigarette smoking-was much higher in Japan than in Western countries, 17 and another--hypertension-was just as high.18 Even the diabetic population in Japan fares better than the diabetic population in Western countries.In 1985, almost 30% of British male diabetics but only Ϸ15% of the Japanese male diabetics had CHD.19 The implication is that if blood cholesterol levels are sufficiently low, the other dominant risk factors, including cigarette smoking, hypertension, and diabetes mellitus, constitute much less of a threat.Are these large differences in incidence between Japan and Western countries based primarily on genetic factors?No. Two cleverly designed epidemiological studies showed that the Japanese who had migrated and taken up permanent residence in Hawaii had higher blood cholesterol levels and a higher incidence of CHD than those who remained on the home island.For those who migrated even further, on to California, the differences were even more striking.20,21 This and other migration studies 22 showed that the differences in CHD risk among different populations are certainly not entirely genetic.Which environmental factors are at play?A number of factors could be involved, but there is reason to believe that the major factors are changes in diet and exercise patterns that predispose to elevated blood cholesterol and obesity.Keys 23 reported as early as 1957 that the fat content of the diet, as a percentage of total calories, rose from 10% to 15% in Japanese on the home island to Ϸ30% in Japanese migrants to Hawaii and to almost 40% in migrants to Los Angeles.A crucially important point needs to be noted here: For whatever reasons, the Japanese have their lower cholesterol levels for their entire lifetimes.Lowering the cholesterol level of a 50-year-old American for just 5 years, even if his cholesterol is successfully brought down to a Japanese-like level, is unlikely to convert his risk to a Japanese-like risk.At 50 years of age, he most likely enters the study with well-established, extensive arterial disease.24,25 It would be unreasonable to expect that all that damage could be reversed in just 5 years.The canonical 5-year trials have given us a minimum estimate of the impact of preventive management.Only after longer trials with younger subjects will we have
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Berenson, G. S., Srinivasan, S. R., Bao, W., Newman, W. P., Tracy, R. E., & Wattigney, W. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806043382302 · Cited by 4,032
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Cited by
Macrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669
Mechanisms of plaque formation and rupture
Bentzon, J. F., Otsuka, F., Virmani, R., & Falk, E. (2014) · Circulation Research · doi:10.1161/circresaha.114.302721 · Cited by 2,391
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Plasma lipoproteins: genetic influences and clinical implications
Hegele, R. A. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2481 · Cited by 462
Wadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.11.010 · Cited by 306
“In individuals with hypobetalipoproteinemia, lifelong very low levels of LDL-C (,15 mg/dL) has not been associated with adverse effects.(117) In a report of 2 individuals, both women with homozygous loss-of-function PCSK9 mutations resulting in LDL-C #15 mg/dL, subjects appeared to be asymptomatic with normal developm…”
Background
Metadata
- Authors
- Steinberg, D., Glass, C. K., & Witztum, J. L.
- Venue
- Circulation
- Published
- 2008-08-05
- Volume
- 118
- Issue
- 6
- Pages
- 672-677
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2167034797
- Cited by
- 100
- References
- 20
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia. https://app.cochat.ai/papers/10.1161/circulationaha.107.753152
- The paper
- Steinberg, D., Glass, C. K., & Witztum, J. L. (2008). Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia. Circulation. https://doi.org/10.1161/circulationaha.107.753152
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.